Research article summary (published 19 Sep 2009):

TMEM25, REPS2 and Meis 1: favourable prognostic and predictive biomarkers for breast cancer.

Full Abstract

BACKGROUND/AIMS: A panel of prognostic and predictive biomarkers would contribute to personalized treatment of breast cancer patients. However, many such biomarkers have yet to be identified and evaluated. The aim of this study was to investigate the relevance of 3 such putative biomarkers. METHODS: TMEM25, REPS2 and Meis 1 expression was investigated by qRT-PCR, in triplicate, in 103 breast tumour biopsies procured in 1993-1994. Normal breast tissue specimens were also analysed for comparative purposes. Univariate and multivariate analyses were used to identify associations between expression of these transcripts as well as patients' clinicopathological and survival data. RESULTS: TMEM25, REPS2 and Meis 1 transcripts were detected in approximately 52, 78 and 40% of tumour specimens, respectively. Expression of each of the 3 genes was indicative of extended survival times from diagnosis [association between relapse-free survival (RFS) and TMEM25, p = 0.0002; REPS2, p = 0.0287; association between overall survival (OS) and TMEM25, p = 0.001; REPS2, p = 0.0131; Meis 1, p = 0.0255]. Presence of TMEM25 and Meis 1 was associated with oestrogen receptor-positive (TMEM25, p < 0.0005; Meis 1, p = 0.011), lower-grade (TMEM25, p = 0.002; Meis 1, p = 0.001) tumours. Multivariate analysis indicated TMEM25 expression to be an independent prognostic factor for extended RFS (p = 0.011) and OS (p = 0.001). Furthermore, for patients who received adjuvant chemotherapy, significantly longer survival times were achieved if their tumours expressed TMEM25 (OS, p = 0.031; RFS, p = 0.0181) and REPS2 (OS, p = 0.011). While expression of these mRNAs was generally absent from triple-negative breast tumours, statistical significance was not achieved. CONCLUSION: Our results suggest that TMEM25, REPS2 and Meis 1 mRNAs may be useful members of a panel of favourable prognostic and predictive markers for breast cancer and an understanding of their function may provide useful information about this disease.

Author information

Author/s: Doolan, P (P); Clynes, M (M); Kennedy, S (S); Mehta, J P (JP); Germano, S (S); Ehrhardt, C (C); Crown, J (J); O'Driscoll, L (L);

Affiliation: National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland.

Journal and publication information

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

Journal: Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine (Tumour Biol), published in Switzerland. (Language: eng)

Reference: 2009-; vol 30 (issue 4) : pp 200-9

Dates: Created 2009/10/09; Completed 2009/11/03;

PMID: 19776672, status: MEDLINE (last retrieval date: 11/3/2009, IMS Date: )

Sourced from the National Library of Medicine. Abstract text and other information may be subject to copyright.

External Links for this article
(including full text providers, if available):

Click Electronic Full-text Provider Links to see options for finding the electronic full text links to this article. Note there may be a subscription or fee required for access to the full text. See our FAQ for information on finding FREE full text articles.

This article may also be located in paper journal collections available in many libraries. Use the Journal and Publication Information above to find the full article.

MeSH headings (categories)

This article was linked to the MESH Headings shown below.

Analysis of Variance Antineoplastic Agents - therapeutic use Biopsy Breast Neoplasms - drug therapy; genetics; pathology Disease-Free Survival Female Homeodomain Proteins - genetics Humans Intracellular Signaling Peptides and Proteins - genetics Lymphatic Metastasis - pathology Middle Aged

Middle Aged Multivariate Analysis Neoplasm Metastasis - pathology Neoplasm Proteins - genetics Neoplasm Staging Prognosis RNA, Messenger - genetics RNA, Neoplasm - genetics; isolation & purification Reverse Transcriptase Polymerase Chain Reaction Tamoxifen - therapeutic use Transcription, Genetic

Associated Chemicals: Antineoplastic Agents (0) ; Homeodomain Proteins (0) ; Intracellular Signaling Peptides and Proteins (0) ; Neoplasm Proteins (0) ; REPS2 protein, human (0) ; RNA, Messenger (0) ; RNA, Neoplasm (0) ; myeloid ecotropic viral integration site 1 protein (0) ; Tamoxifen (10540-29-1)

Related articles

These are the highest related articles currently in the database:

• The V109G polymorphism of the p27 gene CDKN1B indicates a worse outcome in node-negative breast cancer patients. 30 Aug 2004
• Differential effect of anti-apoptotic genes Bcl-xL and c-FLIP on sensitivity of MCF-7 breast cancer cells to paclitaxel and docetaxel. 29 Apr 2005
• Branchio-oto-renal syndrome. 13 Jul 2007
• Patterning of the third pharyngeal pouch into thymus/parathyroid by Six and Eya1. 8 Mar 2006
• Oligonucleotide microarray analysis of estrogen receptor alpha-positive postmenopausal breast carcinomas: identification of HRPAP20 and TIMELESS as outstanding candidate markers to predict the response to tamoxifen. 29 Sep 2007
• Regulation of cyclin D1 RNA stability by SNIP1. 13 Sep 2008
• The new tumor suppressor genes ING: genomic structure and status in cancer. 29 Sep 2008
• Branchio-oto-renal syndrome: detection of EYA1 and SIX1 mutations in five out of six Danish families by combining linkage, MLPA and sequencing analyses. 16 Jul 2007
• Prevalence of mutations in renal developmental genes in children with renal hypodysplasia: results of the ESCAPE study. 11 Sep 2006
• HER-2/neu transcriptionally activates Jab1 expression via the AKT/beta-catenin pathway in breast cancer cells. 30 Aug 2007

See 100+ related articles.

Related Article Map

Legend: - FREE Full text Article. - Abstract only. - Title only. More help.

See a large map of 100+ related articles.